Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Analysis of Liquidity Ratios 
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Merck & Co. Inc., liquidity ratios (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio 1.36 1.36 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11
Quick ratio 0.84 0.88 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66
Cash ratio 0.48 0.49 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Merck & Co. Inc. current ratio deteriorated from Q2 2024 to Q3 2024 but then slightly improved from Q3 2024 to Q4 2024.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Merck & Co. Inc. quick ratio deteriorated from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Merck & Co. Inc. cash ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024.

Current Ratio

Merck & Co. Inc., current ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Current assets 38,782 40,361 38,205 31,445 32,168 31,954 29,977 33,402 35,722 33,561 32,116 31,184 30,266 31,058 28,665 26,909 27,764 26,577 29,343 26,174
Current liabilities 28,420 29,586 26,060 25,099 25,694 23,094 23,394 23,131 24,239 22,998 23,168 22,316 23,872 23,728 21,906 26,361 27,327 20,405 22,178 23,483
Liquidity Ratio
Current ratio1 1.36 1.36 1.47 1.25 1.25 1.38 1.28 1.44 1.47 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.66 0.65 0.81 0.94 0.87 0.96 0.89 0.96 0.96 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14
Amgen Inc. 1.26 1.32 1.26 1.42 1.65 2.86 2.77 3.14 1.41 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59
Bristol-Myers Squibb Co. 1.25 1.24 1.16 1.11 1.43 1.18 1.39 1.42 1.25 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66
Danaher Corp. 1.40 1.37 1.43 1.85 1.68 2.26 2.08 1.89 1.89 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32
Eli Lilly & Co. 1.15 1.27 1.11 1.35 0.94 1.05 1.13 1.30 1.05 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11
Gilead Sciences Inc. 1.60 1.26 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04
Johnson & Johnson 1.11 1.03 1.07 1.17 1.16 1.21 1.12 1.07 0.99 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31
Pfizer Inc. 1.17 1.00 0.86 1.05 0.91 2.38 2.12 1.37 1.22 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03
Regeneron Pharmaceuticals Inc. 4.73 5.28 5.44 5.27 5.69 5.18 5.45 5.45 5.06 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21
Thermo Fisher Scientific Inc. 1.66 1.63 1.72 1.70 1.75 1.63 1.42 1.27 1.48 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32
Vertex Pharmaceuticals Inc. 2.69 2.47 2.52 3.50 3.99 4.08 4.14 4.28 4.83 4.70 4.50 4.75 4.46 4.62 4.61 4.39 4.33 3.72 3.72 3.54

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 38,782 ÷ 28,420 = 1.36

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Merck & Co. Inc. current ratio deteriorated from Q2 2024 to Q3 2024 but then slightly improved from Q3 2024 to Q4 2024.

Quick Ratio

Merck & Co. Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents 13,242 14,593 11,304 5,579 6,841 8,605 5,660 9,707 12,694 11,145 9,675 8,556 8,096 10,016 8,575 6,981 8,062 7,356 11,103 7,425
Short-term investments 447 50 40 252 168 718 680 498 103 453 372 7
Accounts receivable, net of allowance for doubtful accounts 10,278 11,381 11,642 11,366 10,349 10,394 11,030 10,415 9,450 9,482 9,643 9,828 9,230 8,571 7,843 8,235 7,851 8,422 7,577 8,182
Total quick assets 23,967 25,974 22,996 16,985 17,442 19,167 17,408 20,802 22,642 20,730 19,771 18,756 17,326 18,587 16,418 15,216 15,913 15,778 18,680 15,614
 
Current liabilities 28,420 29,586 26,060 25,099 25,694 23,094 23,394 23,131 24,239 22,998 23,168 22,316 23,872 23,728 21,906 26,361 27,327 20,405 22,178 23,483
Liquidity Ratio
Quick ratio1 0.84 0.88 0.88 0.68 0.68 0.83 0.74 0.90 0.93 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.43 0.44 0.59 0.72 0.63 0.71 0.63 0.66 0.69 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88
Amgen Inc. 0.81 0.80 0.75 0.84 0.99 2.41 2.34 2.62 0.95 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10
Bristol-Myers Squibb Co. 0.91 0.84 0.78 0.78 1.04 0.77 0.94 1.01 0.87 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38
Danaher Corp. 0.83 0.84 0.85 1.34 1.18 1.76 1.52 1.34 1.30 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92
Eli Lilly & Co. 0.59 0.63 0.61 0.68 0.52 0.58 0.63 0.79 0.63 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64
Gilead Sciences Inc. 1.20 0.82 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78
Johnson & Johnson 0.78 0.70 0.77 0.84 0.82 0.86 0.84 0.81 0.71 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98
Pfizer Inc. 0.74 0.56 0.42 0.57 0.50 1.78 1.59 0.88 0.80 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60
Regeneron Pharmaceuticals Inc. 3.86 4.34 4.43 4.40 4.82 4.31 4.53 4.54 4.16 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38
Thermo Fisher Scientific Inc. 1.14 1.13 1.24 1.19 1.27 1.13 0.89 0.80 1.06 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48
Vertex Pharmaceuticals Inc. 2.17 2.08 2.10 3.15 3.60 3.74 3.82 3.95 4.46 4.28 4.14 4.37 4.04 4.21 4.16 4.06 4.02 3.46 3.47 3.27

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 23,967 ÷ 28,420 = 0.84

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Merck & Co. Inc. quick ratio deteriorated from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.

Cash Ratio

Merck & Co. Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents 13,242 14,593 11,304 5,579 6,841 8,605 5,660 9,707 12,694 11,145 9,675 8,556 8,096 10,016 8,575 6,981 8,062 7,356 11,103 7,425
Short-term investments 447 50 40 252 168 718 680 498 103 453 372 7
Total cash assets 13,689 14,593 11,354 5,619 7,093 8,773 6,378 10,387 13,192 11,248 10,128 8,928 8,096 10,016 8,575 6,981 8,062 7,356 11,103 7,432
 
Current liabilities 28,420 29,586 26,060 25,099 25,694 23,094 23,394 23,131 24,239 22,998 23,168 22,316 23,872 23,728 21,906 26,361 27,327 20,405 22,178 23,483
Liquidity Ratio
Cash ratio1 0.48 0.49 0.44 0.22 0.28 0.38 0.27 0.45 0.54 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.14 0.17 0.31 0.44 0.34 0.38 0.27 0.24 0.31 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50
Amgen Inc. 0.52 0.44 0.43 0.49 0.60 2.05 2.00 2.22 0.59 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68
Bristol-Myers Squibb Co. 0.46 0.36 0.29 0.37 0.55 0.33 0.43 0.49 0.42 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95
Danaher Corp. 0.31 0.36 0.35 0.90 0.71 1.31 1.02 0.85 0.71 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52
Eli Lilly & Co. 0.12 0.14 0.12 0.14 0.11 0.11 0.15 0.23 0.13 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14
Gilead Sciences Inc. 0.83 0.43 0.26 0.36 0.64 0.57 0.48 0.56 0.57 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34
Johnson & Johnson 0.49 0.39 0.47 0.54 0.50 0.53 0.53 0.54 0.42 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54
Pfizer Inc. 0.48 0.23 0.16 0.29 0.27 1.42 1.29 0.55 0.54 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31
Regeneron Pharmaceuticals Inc. 2.28 2.68 2.80 2.94 3.17 2.75 2.88 2.89 2.46 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95
Thermo Fisher Scientific Inc. 0.42 0.46 0.60 0.52 0.58 0.43 0.22 0.22 0.50 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54
Vertex Pharmaceuticals Inc. 1.72 1.64 1.63 2.68 3.16 3.31 3.35 3.44 3.93 3.74 3.62 3.78 3.51 3.64 3.65 3.56 3.55 3.07 3.03 2.72

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 13,689 ÷ 28,420 = 0.48

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Merck & Co. Inc. cash ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024.